EMEA-003243-PIP01-22
Key facts
| Active substance |
Toripalimab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0408/2022
|
| PIP number |
EMEA-003243-PIP01-22
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions in the category of malignant neoplasms (except CNS, haematopoietic and lymphoid tissue and melanoma)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
TopAlliance Biosciences, Inc.
E-mail: regulatory@topalliancebio.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|